Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Journal of the American Academy of Dermatology · 2024
DOI: 10.1016/j.jaad.2024.03.030 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Linda Stein Gold und 20 weiteren Autor:innen. Beteiligte Einrichtung: Henry Ford Medical Center, Detroit, Michigan. Electronic address: lstein1@hfhs.org. Hauptthemen laut MEDLINE: Cyclopropanes, Psoriasis, Aminopyridines, Benzamides. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Efficacy and/or safety profiles limit topical psoriasis treatments. OBJECTIVE: Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. METHODS: In this open-label phase 2 trial, adult patients (N = 332) with psoriasis who completed the phase 2b parent trial or were newly enrolled applied roflumilast once-daily for 52 weeks. Safety and effectiveness were assessed. RESULTS: Overall, 244 patients (73.5%) completed the trial; 13 patients (3.9%) discontinued due to adverse events (AEs) and 3 (0.9%) due to lack of efficacy. Twelve patients (3.6%) reported treatment-related AEs; none were serious. ≥97% of patients had no irritation. No tachyphylaxis was observed with 44.8% of the patients achieving Investigator Global Assessment (IGA) Clear or Almost Clear at Week 52. LIMITATIONS: Intertriginous-IGA and Psoriasis Area and Severity Index (PASI) were not evaluated in all patients. CONCLUSIONS: In this long-term trial, once-daily roflumilast cream was well-tolerated and efficacious up to 64 weeks in patients in the earlier trial, suggesting it is suitable for chronic treatment, including the face and intertriginous areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henry Ford Medical Center, Detroit, Michigan. Electronic address: lstein1@hfhs.org.
- CCA Medical Research, Toronto, Ontario, Canada; Probity Medical Research, Toronto, Ontario, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Enverus Medical Research, Surrey, British Columbia, Canada.
- Driven Research LLC, Coral Gables, Florida.
- Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- SkiN Centre for Dermatology, Peterborough, Ontario, Canada; Probity Medical Research, Peterborough, Ontario, Canada; Queen's University, Peterborough, Ontario, Canada.
Zitieren
APA
Stein Gold, L., Adam, D. N., Albrecht, L., Alonso-Llamazares, J., Ferris, L. K., Gooderham, M. J., Hong, H. C., Kempers, S. E., Kircik, L. H., Lebwohl, M., Loo, W. J., Nahm, W. K., Papp, K. A., Stewart, D., Toth, D. P., Zirwas, M., Krupa, D., Snyder, S., Burnett, P., …, & Berk, D. R. (2024). Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.03.030
Vancouver
Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2024.03.030
BibTeX
@article{SteinGold2024,
author = {Stein Gold, Linda and Adam, David N and Albrecht, Lorne and Alonso-Llamazares, Javier and Ferris, Laura K and Gooderham, Melinda J and Hong, H Chih-Ho and Kempers, Steven E and Kircik, Leon H and Lebwohl, Mark and Loo, Wei Jing and Nahm, Walter K and Papp, Kim A and Stewart, Daniel and Toth, Darryl P and Zirwas, Matthew and Krupa, David and Snyder, Scott and Burnett, Patrick and Higham, Robert and Berk, David R},
title = {Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial},
journal = {Journal of the American Academy of Dermatology},
year = {2024},
doi = {10.1016/j.jaad.2024.03.030}
}
EUVIMED